Literature DB >> 27725108

Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.

M Alba Mañé-Martínez1, Bob Olsson2, Laura Bau3, Elisabet Matas3, Álvaro Cobo-Calvo3, Ulf Andreasson2, Kaj Blennow2, Lucia Romero-Pinel3, Sergio Martínez-Yélamos3, Henrik Zetterberg4.   

Abstract

In the present study, CSF concentrations of NFL, t-tau, p-tau, GFAP, S-100B, YKL-40, MCP-1, α-sAPP, β-sAPP, and Aβ38, Aβ40, Aβ42 were measured in 324 MS patients to test whether a correlation among the biomarkers exists and whether the profile of CSF biomarkers varies among the different types of MS. The CSF concentrations of NFL were significantly higher in RRMS while CSF concentrations of GFAP were higher in PPMS. CSF concentrations of NFL correlated with YKL-40 in CIS patients while CSF concentrations of GFAP correlated with YKL-40 in RRMS patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27725108     DOI: 10.1016/j.jneuroim.2016.08.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Authors:  Marwa Kaisey; Ghazal Lashgari; Justyna Fert-Bober; Daniel Ontaneda; Andrew J Solomon; Nancy L Sicotte
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

2.  Multiple sclerosis: Biomarkers and genetic variants reflect disease course in multiple sclerosis.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

3.  Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.

Authors:  Xavier Ayrignac; Emmanuelle Le Bars; Claire Duflos; Christophe Hirtz; Aleksandra Maleska Maceski; Clarisse Carra-Dallière; Mahmoud Charif; Frédéric Pinna; Pauline Prin; Nicolas Menjot de Champfleur; Jérémy Deverdun; Tobias Kober; Bénédicte Marechal; Mario Joao Fartaria; Ricardo Corredor Jerez; Pierre Labauge; Sylvain Lehmann
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

4.  YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression.

Authors:  Pol Andrés-Benito; Raúl Domínguez; Maria J Colomina; Franc Llorens; Mònica Povedano; Isidre Ferrer
Journal:  Aging (Albany NY)       Date:  2018-09-13       Impact factor: 5.682

Review 5.  Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study.

Authors:  Laisheng Cai; Jingwei Huang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-09-03       Impact factor: 2.570

6.  Cerebrospinal fluid GAP-43 in early multiple sclerosis.

Authors:  U Rot; Å Sandelius; A Emeršič; H Zetterberg; K Blennow
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-08-07

7.  Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Estrella Morenas-Rodríguez; Daniel Alcolea; Marc Suárez-Calvet; Laia Muñoz-Llahuna; Eduard Vilaplana; Isabel Sala; Andrea Subirana; Marta Querol-Vilaseca; María Carmona-Iragui; Ignacio Illán-Gala; Roser Ribosa-Nogué; Rafael Blesa; Christian Haass; Juan Fortea; Alberto Lleó
Journal:  Sci Rep       Date:  2019-05-24       Impact factor: 4.379

8.  Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Authors:  Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova
Journal:  Front Neurol       Date:  2019-09-23       Impact factor: 4.003

9.  Serum GFAP as a biomarker for disease severity in multiple sclerosis.

Authors:  A Abdelhak; A Huss; J Kassubek; H Tumani; M Otto
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

Review 10.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.

Authors:  Hans Lassmann
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.